Non-steroidal anti-inflammatory drugs, tumour immunity and immunotherapy

Pharmacological Research

Volumn 66, Issue 1, 2012, Pages 7-18

  Hussain, Muzammal ^a   Javeed, Aqeel ^a   Ashraf, Muhammad ^a   Al Zaubai, Nuha ^b   Stewart, Alastair ^b   Mukhtar, Muhammad Mahmood ^c  

^a UNIVERSITY OF VETERINARY AND ANIMAL SCIENCES   (Pakistan)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

EP receptor antagonists; Glucocorticoids; NSAIDs; Prostaglandin E 2; Tumour immunity; Tumour immunotherapy

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETYLSALICYLIC ACID; BCG VACCINE; CANCER VACCINE; CELECOXIB; CETUXIMAB; CYCLOOXYGENASE 2 INHIBITOR; DENDRITIC CELL VACCINE; DICLOFENAC; DNA VACCINE; ETODOLAC; GEMCITABINE; INDOMETACIN; INTERLEUKIN 1; INTERLEUKIN 2; KETOPROFEN; KETOROLAC; LEXATUMUMAB; LYSINE MONOACETYLSALICYLATE; MECLOFENAMIC ACID; MONOCLONAL ANTIBODY; NADOLOL; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PICIBANIL; PROPRANOLOL; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; ROFECOXIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACTIVE IMMUNIZATION; ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; BLADDER CANCER; BREAST CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CARCINOMATOUS PERITONITIS; CHEMOPROPHYLAXIS; CHRONIC INFLAMMATION; COLORECTAL CANCER; CYTOKINE RELEASE; DENDRITIC CELL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIZATION; EFFECTOR CELL; FIBROSARCOMA; HEAD AND NECK CANCER; HOST RESISTANCE; HUMAN; IMMUNOMODULATION; LEUKEMIA; LYMPH NODE METASTASIS; MELANOMA; METASTASIS; NATURAL KILLER CELL; NONHUMAN; PANCREAS CANCER; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TRANSITIONAL CELL CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COMBINED MODALITY THERAPY; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; NEOPLASMS; PROSTAGLANDINS; SIGNAL TRANSDUCTION; TUMOR ESCAPE;

EID: 84860480636     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2012.02.003     Document Type: Review

References (164)

1. J.R. Vane Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs Nat New Biol 231 1971 232 235
2. P.E. Lipsky Role of cyclooxygenase-1 and -2 in health and disease Am J Orthop (Belle Mead NJ) 28 1999 8 12
3. R.A. Adelizzi COX-1 and COX-2 in health and disease J Am Osteopath Assoc 99 1999 S7 S12
4. S. Zha, V. Yegnasubramanian, W.G. Nelson, W.B. Isaacs, and A.M. De Marzo Cyclooxygenases in cancer: progress and perspective Cancer Lett 215 2004 1 20 (Pubitemid 39221453)
5. K. Wakabayashi NSAIDs as cancer preventive agents Asian Pac J Cancer Prev 1 2000 97 113
6. P. Ricchi, R. Zarrilli, A. Di Palma, and A.M. Acquaviva Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy Br J Cancer 88 2003 803 807 (Pubitemid 36520863)
7. Y. Dai, and W.H. Wang Non-steroidal anti-inflammatory drugs in prevention of gastric cancer World J Gastroenterol 12 2006 2884 2889 (Pubitemid 43805458)
8. C.M. Ulrich, J. Bigler, and J.D. Potter Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics Nat Rev Cancer 6 2006 130 140 (Pubitemid 43361545)
9. D. Pereg, and M. Lishner Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer J Intern Med 258 2005 115 123 (Pubitemid 41025968)
10. J. Wasserman, H. Blomgren, S. Rotstein, B. Petrini, and S. Hammarstrom Immunosuppression in irradiated breast cancer patients: in vitro effect of cyclooxygenase inhibitors Bull N Y Acad Med 65 1989 36 44 (Pubitemid 19065026)
11. T.L. Whiteside Immune responses to malignancies J Allergy Clin Immunol 125 2010 S272 S283
12. H.J. Steer, R.A. Lake, A.K. Nowak, and B.W. Robinson Harnessing the immune response to treat cancer Oncogene 29 2010 6301 6313
13. V. Bronte, and S. Mocellin Suppressive influences in the immune response to cancer J Immunother 32 2009 1 11
14. S. Rajput, and A. Wilber Roles of inflammation in cancer initiation, progression, and metastasis Front Biosci (Schol Ed) 2 2010 176 183
15. K.J. O'Byrne, and A.G. Dalgleish Chronic immune activation and inflammation as the cause of malignancy Br J Cancer 85 2001 473 483 (Pubitemid 32808267)
16. J. Rodriguez-Vita, and T. Lawrence The resolution of inflammation and cancer Cytokine Growth Factor Rev 21 2010 61 65
17. A. Ben-Baruch Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators Semin Cancer Biol 16 2006 38 52 (Pubitemid 43139708)
18. P. Eschwege, V. de Ledinghen, T. Camilli, S. Kulkarni, G. Dalbagni, and S. Droupy Arachidonic acid and prostaglandins, inflammation and oncology Presse Med 30 2001 508 510 (Pubitemid 32238359)
19. D. Wang, and R.N. Dubois Prostaglandins and cancer Gut 55 2006 115 122 (Pubitemid 41820645)
20. Y. Sugimoto, and S. Narumiya Prostaglandin E receptors J Biol Chem 282 2007 11613 11617 (Pubitemid 47100657)
21. C.M. Balch, P.A. Dougherty, G.A. Cloud, and A.B. Tilden Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients Surgery 95 1984 71 77 (Pubitemid 14215461)
22. J.M. Chemnitz, J. Driesen, S. Classen, J.L. Riley, S. Debey, and M. Beyer Prostaglandin E2 impairs CD4+ T cell activation by inhibition of lck: implications in Hodgkin's lymphoma Cancer Res 66 2006 1114 1122 (Pubitemid 43165980)
23. Y. Su, X. Huang, T. Raskovalova, L. Zacharia, A. Lokshin, and E. Jackson Cooperation of adenosine and prostaglandin E2 (PGE2) in amplification of cAMP-PKA signaling and immunosuppression Cancer Immunol Immunother 57 2008 1611 1623
24. M. Zeddou, R. Greimers, N. de Valensart, B. Nayjib, K. Tasken, and J. Boniver Prostaglandin E2 induces the expression of functional inhibitory CD94/NKG2A receptors in human CD8+ T lymphocytes by a cAMP-dependent protein kinase A type I pathway Biochem Pharmacol 70 2005 714 724 (Pubitemid 41058706)
25. S. Yaqub, and K. Tasken Role for the cAMP-protein kinase A signaling pathway in suppression of antitumor immune responses by regulatory T cells Crit Rev Oncogenesis 14 2008 57 77
26. L. Martinet, C. Jean, G. Dietrich, J.J. Fournie, and R. Poupot PGE2 inhibits natural killer and gamma delta T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling Biochem Pharmacol 80 2010 838 845
27. S. Chattopadhyay, S. Bhattacharyya, B. Saha, J. Chakraborty, S. Mohanty, and D.M. Sakib Hossain Tumor-shed PGE(2) impairs IL2Rgammac-signaling to inhibit CD4T cell survival: regulation by the aflavins PLoS One 4 2009 e7382
28. M. Ahmadi, D.C. Emery, and D.J. Morgan Prevention of both direct and cross-priming of antitumor CD8+ T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo Cancer Res 68 2008 7520 7529
29. F. Baratelli, Y. Lin, L. Zhu, S.C. Yang, N. Heuze-Vourc'h, and G. Zeng Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells J Immunol 175 2005 1483 1490 (Pubitemid 41023048)
30. S. Sharma, S.C. Yang, L. Zhu, K. Reckamp, B. Gardner, and F. Baratelli Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer Cancer Res 65 2005 5211 5220 (Pubitemid 40827331)
31. T.J. Stewart, and M.J. Smyth Improving cancer immunotherapy by targeting tumor-induced immune suppression Cancer Metastasis Rev 30 2011 125 140
32. T.L. Whiteside Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression Expert Opin Biol Ther 10 2011 1019 1035
33. A.J. Dannenberg, and K. Subbaramaiah Targeting cyclooxygenase-2 in human neoplasia: rationale and promise Cancer Cell 4 2003 431 436 (Pubitemid 38050040)
34. L.J. Marnett The COXIB experience: a look in the rearview mirror Annu Rev Pharmacol Toxicol 49 2009 265 290
35. A. Sica, P. Larghi, A. Mancino, L. Rubino, C. Porta, and M.G. Totaro Macrophage polarization in tumour progression Semin Cancer Biol 18 2008 349 355
36. D.J. Cameron, and P. O'Brien Relationship of the suppression of macrophage mediated tumor cytotoxicity in conjunction with secretion of prostaglandin from the macrophages of breast cancer patients Int J Immunopharmacol 4 1982 445 450 (Pubitemid 12042824)
37. D.J. Cameron, M. Rittenbury, and J. Majeski Ability of cancer patients' macrophages to kill autologous tumor targets. Effect of prostaglandin inhibitors on cytotoxicity Cancer 53 1984 2053 2057 (Pubitemid 14101773)
38. D.J. Cameron, and B.V. Stromberg The ability of macrophages from head and neck cancer patients to kill tumor cells. Effect of prostaglandin inhibitors on cytotoxicity Cancer 54 1984 2403 2408 (Pubitemid 15223380)
39. B. Petrini, G. Wolk, J. Wasserman, I. Vedin, O. Strannegard, and H. Blomgren Indomethacin modulation of monocyte cytokine release following pelvic irradiation for cancer Eur J Cancer 27 1991 591 594
40. S. Ikemoto, T. Kishimoto, H. Iimori, Y. Morikawa, N. Hayahara, and M. Maekawa Defective interleukin-1 production of monocytes in patients with bladder cancer Br J Urol 65 1990 181 185 (Pubitemid 20058328)
41. Y. Ohshika, N. Umesaki, and T. Sugawa Immunomodulating capacity of the monocyte-macrophage system in patients with uterine cervical cancer Nippon Sanka Fujinka Gakkai Zasshi 40 1988 601 608
42. S. Lang, L. Lauffer, C. Clausen, I. Lohr, B. Schmitt, and D. Holzel Impaired monocyte function in cancer patients: restoration with a cyclooxygenase-2 inhibitor Faseb J 17 2003 286 288
43. S. Lang, S. Tiwari, M. Andratschke, I. Loehr, L. Lauffer, and C. Bergmann Immune restoration in head and neck cancer patients after in vivo COX-2 inhibition Cancer Immunol Immunother 56 2007 1645 1652 (Pubitemid 47094395)
44. C. Iwata, M.R. Kano, A. Komuro, M. Oka, K. Kiyono, and E. Johansson Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis Cancer Res 67 2007 10181 10189 (Pubitemid 350070790)
45. J.J. Chen, P.L. Yao, A. Yuan, T.M. Hong, C.T. Shun, and M.L. Kuo Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer Clin Cancer Res 9 2003 729 737 (Pubitemid 36182607)
46. T. Han, and H. Takita Indomethacin-mediated enhancement of lymphocyte response to mitogens in healthy subjects and lung cancer patients Cancer 46 1980 2416 2420 (Pubitemid 11253701)
47. C.N. Baxevanis, G.J. Reclos, A.D. Gritzapis, G.V. Dedousis, I. Missitzis, and M. Papamichail Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer Cancer 72 1993 491 501 (Pubitemid 23193457)
48. H. Koyama, T. Narisawa, M. Kodama, K. Ishikawa, H. Kusaka, and Y. Yamazaki Potent effects of the prostaglandin synthesis inhibitor indomethacin on the cellular immune response in gastrointestinal cancer patients Nippon Gan Chiryo Gakkai Shi 24 1989 1027 1033 (Pubitemid 19179830)
49. A.B. Tilden, and C.M. Balch Indomethacin enhancement of immunocompetence in melanoma patients Surgery 90 1981 77 84 (Pubitemid 11041610)
50. H. Aso, K. Tamura, O. Yoshie, T. Nakamura, S. Kikuchi, and N. Ishida Impaired NK response of cancer patients to IFN-alpha but not to IL-2: correlation with serum immunosuppressive acidic protein (IAP) and role of suppressor macrophage Microbiol Immunol 36 1992 1087 1097 (Pubitemid 23000642)
51. K. Tarte, and B. Klein Dendritic cell-based vaccine: a promising approach for cancer immunotherapy Leukemia 13 1999 653 663 (Pubitemid 29243614)
52. T. Hahn, I. Alvarez, J.J. Kobie, L. Ramanathapuram, S. Dial, and A. Fulton Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer Int J Cancer 118 2006 2220 2231
53. G.D. Basu, T.L. Tinder, J.M. Bradley, T. Tu, C.L. Hattrup, and B.A. Pockaj Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO J Immunol 177 2006 2391 2402 (Pubitemid 44201000)
54. P. Chiarella, M. Vulcano, J. Bruzzo, M. Vermeulen, S. Vanzulli, and A. Maglioco Anti-inflammatory pretreatment enables an efficient dendritic cell-based immunotherapy against established tumors Cancer Immunol Immunother 57 2008 701 718 (Pubitemid 351641031)
55. S.J. Dovedi, J.A. Kirby, H. Atkins, B.R. Davies, and J.D. Kelly Cyclooxygenase-2 inhibition: a potential mechanism for increasing the efficacy of bacillus calmette-guerin immunotherapy for bladder cancer J Urol 174 2005 332 337 [discussion 337] (Pubitemid 40825752)
56. S.J. Dovedi, J.A. Kirby, B.R. Davies, H. Leung, and J.D. Kelly Celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma Eur Urol 54 2008 621 630
57. A.J. Walmesley, J. Zweiri, S.E. Christmas, and A.J. Watson Rofecoxib has different effects on chemokine production in colorectal cancer cells and tumor immune splenocytes J Immunother 30 2007 614 623 (Pubitemid 47229696)
58. L. Zamai, C. Ponti, P. Mirandola, G. Gobbi, S. Papa, and L. Galeotti NK cells and cancer J Immunol 178 2007 4011 4016 (Pubitemid 46492347)
59. E.M. Levy, M.P. Roberti, and J. Mordoh Natural killer cells in human cancer: from biological functions to clinical applications J Biomed Biotechnol 2011 2010 676198
60. P. Flodgren, and H.O. Sjogren Influence in vitro on NK and K cell activities by cimetidine and indomethacin with and without simultaneous exposure to interferon Cancer Immunol Immunother 19 1985 28 34 (Pubitemid 15110992)
61. N. Kundu, T.C. Walser, X. Ma, and A.M. Fulton Cyclooxygenase inhibitors modulate NK activities that control metastatic disease Cancer Immunol Immunother 54 2005 981 987 (Pubitemid 41187706)
62. T.A. Colacchio, M.P. Yeager, and L.W. Hildebrandt Perioperative immunomodulation in cancer surgery Am J Surg 167 1994 174 179 (Pubitemid 24264161)
63. Z. Wang, Y. Chen, R. Zheng, D. Qin, X. Chen, and Y. Wang In vitro effects of prostaglandin E2 or indomethacin on the proliferation of lymphokine-activated killer cells and their cytotoxicity against bladder tumor cells in patients with bladder cancer Prostaglandins 54 1997 769 779
64. W.R. Reed, and R.L. DeGowin Suppressive effects of pentoxifylline on natural killer cell activity J Lab Clin Med 119 1992 763 771
65. G.G. Page, and S. Ben-Eliyahu Indomethacin attenuates the immunosuppressive and tumor-promoting effects of surgery J Pain 3 2002 301 308 (Pubitemid 34879378)
66. T.Y. Chao, C.S. Ting, M.Y. Yeh, J.Y. Chang, C.C. Wang, and T.M. Chu Effects of indomethacin on lymphokine-activated killer cell activities in cancer patients Tumour Biol 16 1995 230 242
67. P.H. Grohmann, F. Porzsolt, I. Quirt, R.G. Miller, and R.A. Phillips Stimulation of human NK cell activity by cultured cells. II. Ingestion of aspirin by blood donors suppresses induced NK activity Clin Exp Immunol 44 1981 611 614 (Pubitemid 11066960)
68. F. Porzsolt, and W. Wolf Modulation of natural killer activity by aspirin: I. In vitro effect of aspirin J Interferon Res 3 1983 11 17 (Pubitemid 14222315)
69. N. Tanaka, Y. Okamoto, K. Gotoh, A. Hizuta, S. Yunoki, and K. Orita Combined therapy with interleukin 2 and indomethacin in mice inoculated with MH134 hepatoma Acta Med Okayama 49 1995 241 245
70. V. Shparyk Ia The dynamic indices of the natural killer cells in the chemotherapy of patients with digestive organ cancer Vrach Delo 1990 14 16
71. M. Benish, I. Bartal, Y. Goldfarb, B. Levi, R. Avraham, and A. Raz Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis Ann Surg Oncol 15 2008 2042 2052
72. Y. Goldfarb, L. Sorski, M. Benish, B. Levi, R. Melamed, and S. Ben-Eliyahu Improving postoperative immune status and resistance to cancer metastasis: a combined perioperative approach of immunostimulation and prevention of excessive surgical stress responses Ann Surg 253 2011 798 810
73. A. Glasner, R. Avraham, E. Rosenne, M. Benish, O. Zmora, and S. Shemer Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor J Immunol 184 2010 2449 2457
74. R. Avraham, M. Benish, S. Inbar, I. Bartal, E. Rosenne, and S. Ben-Eliyahu Synergism between immunostimulation and prevention of surgery-induced immune suppression: an approach to reduce post-operative tumor progression Brain Behav Immun 24 2010 952 958
75. K.L. Knutson, and M.L. Disis Tumor antigen-specific T helper cells in cancer immunity and immunotherapy Cancer Immunol Immunother 54 2005 721 728 (Pubitemid 40977140)
76. J.E. Talmadge, K.C. Hood, L.C. Zobel, L.R. Shafer, M. Coles, and B. Toth Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion Int Immunopharmacol 7 2007 140 151 (Pubitemid 46043318)
77. T. Tanaka, P.A. Delong, K. Amin, A. Henry, R. Kruklitis, and V. Kapoor Treatment of lung cancer using clinically relevant oral doses of the cyclooxygenase-2 inhibitor rofecoxib: potential value as adjuvant therapy after surgery Ann Surg 241 2005 168 178 (Pubitemid 40041006)
78. C. Lonnroth, M. Andersson, A. Arvidsson, S. Nordgren, H. Brevinge, and K. Lagerstedt Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer Cancer Immun 8 2008 5
79. A.R. Haas, J. Sun, A. Vachani, A.F. Wallace, M. Silverberg, and V. Kapoor Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine Clin Cancer Res 12 2006 214 222 (Pubitemid 43166197)
80. G. Ferrandina, F.O. Ranelletti, F. Legge, V. Salutari, E. Martinelli, and A. Fattorossi Celecoxib up-regulates the expression of the zeta chain of T cell receptor complex in tumor-infiltrating lymphocytes in human cervical cancer Clin Cancer Res 12 2006 2055 2060
81. K.J. McCormick, and W.R. Panje Indomethacin-induced augmentation of lymphoproliferative responses in patients with head and neck cancer Cancer Immunol Immunother 21 1986 226 232 (Pubitemid 16080415)
82. R.D. Maca, and W.R. Panje Indomethacin sensitive suppressor cell activity in head and neck cancer patients pre- and postirradiation therapy Cancer 50 1982 483 489 (Pubitemid 12097417)
83. C.M. Balch, P.A. Dougherty, and A.B. Tilden Excessive prostaglandin E2 production by suppressor monocytes in head and neck cancer patients Ann Surg 196 1982 645 650 (Pubitemid 13208361)
84. T. Han, T. Nemoto, E.J. Ledesma, and S. Bruno Enhancement of T lymphocyte proliferative response to mitogens by indomethacin in breast and colorectal cancer patients Int J Immunopharmacol 5 1983 11 15 (Pubitemid 13144333)
85. Y. Kurosu, T. Arai, and K. Morita Indomethacin enhancement of lymphocyte responses to phytohemagglutinin in breast, stomach and colorectal cancer patients Jpn J Surg 18 1988 152 157
86. V. Alberola, A. Gonzalez-Molina, A. Trenor, B. San Martin, A. Lluch, and F. Palau Mechanism of suppression of the depressed lymphocyte response in lung cancer patients Allergol Immunopathol (Madr) 13 1985 213 219
87. N. Stanojevic-Bakic, L. Vuckovic-Dekic, O. Frim, L. Rajner, and I. Spuzic Enhancement of phytohemagglutinin-induced lymphoproliferative response by indomethacin, Thymex L or their combination in lung cancer patients Anticancer Drugs 4 1993 565 569 (Pubitemid 23317925)
88. N. Stanojevic-Bakic, L. Vuckovic-Dekic, S. Susnjar, and I. Spuzic In vitro effect of indomethacin on mitogen-induced lymphoproliferative response in lung cancer patients Neoplasma 39 1992 129 132
89. J. Richner, E.P. Ambinder, K. Hoffmann, E.J. Feuer, and G. Bekesi Number of helper T cells and phytohemagglutinin stimulation correlate in cancer patients Cancer Immunol Immunother 34 1991 138 142
90. R.D. Maca, J.G. Burford, and R.T. Taylor The effects of indomethacin and interleukin-2 on the proliferation of lymphocytes from patients with lung cancer J Clin Immunol 5 1985 158 165 (Pubitemid 15123195)
91. D.P. Braun, and J.E. Harris Abnormal indomethacin-sensitive suppression in peripheral blood mononuclear cells of cancer patients restricts augmentation by interleukin-2 J Biol Response Mod 3 1984 533 540 (Pubitemid 14013615)
92. M. Reinerova, Z. Veselovska, C. Ausch, and H.R. Rosen Immunosuppressive activity of lymphocyte mitogenesis by breast cancer-associated p43 Neoplasma 43 1996 363 366 (Pubitemid 26407960)
93. H.R. Rosen, C. Ausch, G. Reiner, M. Reinerova, J. Svec, and H. Tuchler Immunosuppression by breast cancer associated p43-effect of immunomodulators Breast Cancer Res Treat 41 1996 171 176 (Pubitemid 26360146)
94. R. Vitiello, C. Giordano, A. Macchieraldo, G. Pecorari, and A. Sartoris Prostaglandins, suppressive action cells and carcinoma of the larynx: preliminary data Acta Otorhinolaryngol Ital 10 1990 73 78
95. I.V. Kas'ianenko, V.M. Pivniuk, A.M. Lisitsa, N.A. Kovalenko, and M.A. Bagirian The immunomodulating role of indomethacin in the chemoradiation treatment of inoperable patients with lung cancer Vopr Onkol 38 1992 1183 1187 (Pubitemid 24016181)
96. T.D. Moroz, A.K. Zinevich, I.V. Kas'ianenko, and V.L. Moroz Effect of indomethacin on the immunological indices of patients with inoperable stomach cancer Eksp Onkol 11 1989 66 68 (Pubitemid 19086744)
97. G.M. Mavligit, L.S. Raphael, D.B. Calvo 3rd, and W.L. Wong Indomethacin-induced, monocyte-dependent restoration of local graft-versus-host reaction among cells from cancer patients J Natl Cancer Inst 65 1980 317 320 (Pubitemid 10087422)
98. H. Blomgren, S. Rotstein, J. Wasserman, B. Petrini, and S. Hammarstrom In vitro capacity of various cyclooxygenase inhibitors to revert immune suppression caused by radiation therapy for breast cancer Radiother Oncol 19 1990 329 335
99. J.Q. Liu, F.X. Chen, X.J. Gong, H.Z. Li, K. Cai, and B.F. Zhang Mechanistic study of nimesulide on enhancing gammadeltaT cell-mediated killing of gastric cancer cells Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 26 2010 261 263 266
100. M.J. Droller, and D. Gomolka Indomethacin and poly I:C in the inhibition of carcinogen-induced bladder cancer in an experimental animal model J Urol 131 1984 1212 1217 (Pubitemid 14082452)
101. T. Yamaguchi, and S. Sakaguchi Regulatory T cells in immune surveillance and treatment of cancer Semin Cancer Biol 16 2006 115 123 (Pubitemid 43172060)
102. M. Terabe, and J.A. Berzofsky Immunoregulatory T cells in tumor immunity Curr Opin Immunol 16 2004 157 162 (Pubitemid 38332026)
103. S. Nizar, J. Copier, B. Meyer, M. Bodman-Smith, C. Galustian, and D. Kumar T-regulatory cell modulation: the future of cancer immunotherapy Br J Cancer 100 2009 1697 1703
104. F. Baratelli, J.M. Lee, S. Hazra, Y. Lin, T.C. Walser, and D. Schaue PGE(2) contributes to TGF-beta induced T regulatory cell function in human non-small cell lung cancer Am J Transl Res 2 2010 356 367
105. S. Yaqub, K. Henjum, M. Mahic, F.L. Jahnsen, E.M. Aandahl, and B.A. Bjornbeth Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner Cancer Immunol Immunother 57 2008 813 821 (Pubitemid 351660125)
106. A. Cesario, B. Rocca, and S. Rutella The interplay between indoleamine 2,3-dioxygenase 1 (IDO1) and cyclooxygenase (COX)-2 in chronic inflammation and cancer Curr Med Chem 18 2011 2263 2271
107. S.Y. Lee, H.K. Choi, K.J. Lee, J.Y. Jung, G.Y. Hur, and K.H. Jung The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells J Immunother 32 2009 22 28
108. P. Mukherjee, G.D. Basu, T.L. Tinder, D.B. Subramani, J.M. Bradley, and M. Arefayene Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition J Immunol 182 2009 216 224
109. M. Schuster, A. Nechansky, and R. Kircheis Cancer immunotherapy Biotechnol J 1 2006 138 147
110. J.D. Veltman, M.E. Lambers, M. van Nimwegen, R.W. Hendriks, H.C. Hoogsteden, and J.G. Aerts COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function BMC Cancer 10 2010 464
111. H.E. Zeytin, A.C. Patel, C.J. Rogers, D. Canter, S.D. Hursting, and J. Schlom Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice Cancer Res 64 2004 3668 3678 (Pubitemid 38657947)
112. S. Morecki, E. Yacovlev, Y. Gelfand, V. Trembovler, E. Shohami, and S. Slavin Induction of antitumor immunity by indomethacin Cancer Immunol Immunother 48 2000 613 620 (Pubitemid 30064663)
113. S. Morecki, L. Yacovlev, and S. Slavin Effect of indomethacin on tumorigenicity and immunity induction in a murine model of mammary carcinoma Int J Cancer 75 1998 894 899 (Pubitemid 28134115)
114. J.H. Gunther, M. Frambach, I. Deinert, S. Brandau, D. Jocham, and A. Bohle Effects of acetylic salicylic acid and pentoxifylline on the efficacy of intravesical BCG therapy in orthotopic murine bladder cancer (MB49) J Urol 161 1999 1702 1706 (Pubitemid 29420866)
115. W.Z. Sun, M.C. Chang, P.N. Hsiao, C.A. Chen, Y.T. Hsu, and C.Y. Hsieh Morphine-sparing effect by COX-1 inhibitor sustains analgesic function without compromising antigen-specific immunity and antitumor effect of naked DNA vaccine Int J Immunopathol Pharmacol 23 2010 91 104
116. M. Beyer, and J.L. Schultze Immunoregulatory T cells: role and potential as a target in malignancy Curr Oncol Rep 10 2008 130 136 (Pubitemid 351395473)
117. M.A. Morse, T.M. Clay, P. Mosca, and H.K. Lyerly Immunoregulatory T cells in cancer immunotherapy Expert Opin Biol Ther 2 2002 827 834 (Pubitemid 36033249)
118. D.G. Alleva, C.J. Burger, and K.D. Elgert Tumor-induced macrophage tumor necrosis factor-alpha production suppresses autoreactive T cell proliferation Immunobiology 188 1993 430 445 (Pubitemid 23264759)
119. D.G. Alleva, C.J. Burger, and K.D. Elgert Tumour growth causes suppression of autoreactive T-cell proliferation by disrupting macrophage responsiveness to interferon-gamma Scand J Immunol 39 1994 31 38 (Pubitemid 24232894)
120. Y. Moriguchi, N. Kan, T. Okino, T. Harada, S. Yamasaki, and Y. Ichinose A new model of active specific immunotherapy using interleukin-1 and sonicated tumor supernatant in murine tumor system J Surg Oncol 62 1996 78 85 (Pubitemid 26196503)
121. M. Lu, A. Strohecker, F. Chen, T. Kwan, J. Bosman, and V.C. Jordan Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels Clin Cancer Res 14 2008 3168 3176
122. Y.J. Liu, Y.F. Ma, J. Zhang, Y.P. Zhao, H.L. Bai, and S.L. Li Synergistic lethal effect of mDRA-6 and nimesulide on human hepatocellular cancer cell line SMMC-7721 Ai Zheng 27 2008 374 378
123. M. Mann, H. Sheng, J. Shao, C.S. Williams, P.I. Pisacane, and M.X. Sliwkowski Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth Gastroenterology 120 2001 1713 1719 (Pubitemid 32523489)
124. P.H. Tseng, Y.C. Wang, S.C. Weng, J.R. Weng, C.S. Chen, and R.W. Brueggemeier Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor Mol Pharmacol 70 2006 1534 1541
125. C.T. Dang, A.J. Dannenberg, K. Subbaramaiah, M.N. Dickler, M.M. Moasser, and A.D. Seidman Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments Clin Cancer Res 10 2004 4062 4067 (Pubitemid 38812482)
126. E. Chan, B. Lafleur, M.L. Rothenberg, N. Merchant, A.C. Lockhart, and B. Trivedi Dual blockade of the EGFR and COX-2 pathways: a phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancer Am J Clin Oncol 34 2011 581 586
127. B. Hennemann, G. Beckmann, A. Eichelmann, A. Rehm, and R. Andreesen Phase I trial of adoptive immunotherapy of cancer patients using monocyte-derived macrophages activated with interferon gamma and lipopolysaccharide Cancer Immunol Immunother 45 1998 250 256 (Pubitemid 128759559)
128. T.J. Eberlein, D.D. Schoof, H.R. Michie, A.F. Massaro, U. Burger, and D.W. Wilmore Ibuprofen causes reduced toxic effects of interleukin 2 administration in patients with metastatic cancer Arch Surg 124 1989 542 547 (Pubitemid 19127598)
129. P.K. Lala, and R.S. Parhar Cure of B16F10 melanoma lung metastasis in mice by chronic indomethacin therapy combined with repeated rounds of interleukin 2: characteristics of killer cells generated in situ Cancer Res 48 1988 1072 1079 (Pubitemid 18075509)
130. D. Flieger, M. Varvenne, R. Kleinschmidt, and I.G. Schmidt-Wolf Influence of immunomodulatory drugs on the cytotoxicity induced by monoclonal antibody 17-1A and interleukin-2 Cell Immunol 246 2007 26 33 (Pubitemid 47087768)
131. J.A. Sosman, P.C. Kohler, J.A. Hank, K.H. Moore, R. Bechhofer, and B. Storer Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin J Natl Cancer Inst 80 1988 1451 1461 (Pubitemid 18264888)
132. K. Nakata, S. Kashimoto, H. Yoshida, T. Oku, and S. Nakamura Augmented antitumor effect of recombinant human interleukin-1 alpha by indomethacin Cancer Res 48 1988 584 588 (Pubitemid 18056526)
133. J.E. Janik, L.L. Miller, D.L. Longo, G.C. Powers, W.J. Urba, and W.C. Kopp Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma J Natl Cancer Inst 88 1996 44 49 (Pubitemid 26006870)
134. J.L. Barrera, E. Verastegui, A. Meneses, J. Zinser, J. de la Garza, and J.W. Hadden Combination immunotherapy of squamous cell carcinoma of the head and neck: a phase 2 trial Arch Otolaryngol Head Neck Surg 126 2000 345 351 (Pubitemid 30140389)
135. A. Duenas-Gonzalez, E. Verastegui, C. Lopez-Graniel, A. Gonzalez, A. Mota, and J.L. Barrera-Franco A pilot study of perilymphatic leukocyte cytokine mixture (IRX-2) as neoadjuvant treatment for early stage cervical carcinoma Int Immunopharmacol 2 2002 1007 1016 (Pubitemid 34756391)
136. R. Feinmesser, B. Hardy, R. Sadov, A. Shwartz, P. Chretien, and M. Feinmesser Report of a clinical trial in 12 patients with head and neck cancer treated intratumorally and peritumorally with multikine Arch Otolaryngol Head Neck Surg 129 2003 874 881 (Pubitemid 36966434)
137. S.M. Freeman, J.L. Franco, D.E. Kenady, L. Baltzer, Z. Roth, and H.J. Brandwein A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck Am J Clin Oncol 34 2011 173 178
138. J. Hadden, E. Verastegui, J.L. Barrera, M. Kurman, A. Meneses, and J.W. Zinser A trial of IRX-2 in patients with squamous cell carcinomas of the head and neck Int Immunopharmacol 3 2003 1073 1081 (Pubitemid 36830852)
139. J.W. Hadden, J. Endicott, P. Baekey, P. Skipper, and E.M. Hadden Interleukins and contrasuppression induce immune regression of head and neck cancer Arch Otolaryngol Head Neck Surg 120 1994 395 403 (Pubitemid 24129004)
140. A. Meneses, E. Verastegui, J.L. Barrera, J. de la Garza, and J.W. Hadden Lymph node histology in head and neck cancer: impact of immunotherapy with IRX-2 Int Immunopharmacol 3 2003 1083 1091 (Pubitemid 36830853)
141. A. Meneses, E. Verastegui, J.L. Barrera, J. Zinser, J. de la Garza, and J.W. Hadden Histologic findings in patients with head and neck squamous cell carcinoma receiving perilymphatic natural cytokine mixture (IRX-2) prior to surgery Arch Pathol Lab Med 122 1998 447 454 (Pubitemid 28237539)
142. J. Timar, A. Ladanyi, C. Forster-Horvath, J. Lukits, B. Dome, and E. Remenar Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4/CD8 ratio and tumor microenvironment: a multicenter phase II clinical trial J Clin Oncol 23 2005 3421 3432
143. E. Verastegui, J.L. Barrera, J. Zinser, R. Del Rio, A. Meneses, and J. De La Garza A natural cytokine mixture (IRX-2) and interference with immune suppression induce immune mobilization and regression of head and neck cancer Int J Immunopharmacol 19 1997 619 627 (Pubitemid 28270796)
144. G.T. Wolf, W.E. Fee Jr., R.W. Dolan, J.S. Moyer, M.J. Kaplan, and P.M. Spring Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer Head Neck 33 2011 1666 1674
145. D. Sidler, P. Renzulli, C. Schnoz, B. Berger, S. Schneider-Jakob, and C. Fluck Colon cancer cells produce immunoregulatory glucocorticoids Oncogene 30 2011 2411 2419
146. K. Krukowski, J. Eddy, K.L. Kosik, T. Konley, L.W. Janusek, and H.L. Mathews Glucocorticoid dysregulation of natural killer cell function through epigenetic modification Brain Behav Immun 25 2010 239 249
147. A. Moustaki, K.V. Argyropoulos, C.N. Baxevanis, M. Papamichail, and S.A. Perez Effect of the simultaneous administration of glucocorticoids and IL-15 on human NK cell phenotype, proliferation and function Cancer Immunol Immunother 60 2011 1683 1695
148. S.A. Perez, L.G. Mahaira, F.J. Demirtzoglou, P.A. Sotiropoulou, P. Ioannidis, and E.G. Iliopoulou A potential role for hydrocortisone in the positive regulation of IL-15-activated NK-cell proliferation and survival Blood 106 2005 158 166 (Pubitemid 40967188)
149. M. Kato, S. Goto, and G. Soma Lymphokine-activated killer cell therapy
150. M. Naito, K. Itoh, N. Komatsu, Y. Yamashita, T. Shirakusa, and A. Yamada Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients Prostate 68 2008 1753 1762
151. Y. Takagi, T. Kikuchi, M. Niimura, and T. Ohno Effects of glucocorticoids on antitumor effects of immunizations with fusions of dendritic and tumor cells Anticancer Res 23 2003 2553 2558 (Pubitemid 36897127)
152. C. Brandl, C. Haas, S. d'Argouges, T. Fisch, P. Kufer, and K. Brischwein The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct Cancer Immunol Immunother 56 2007 1551 1563 (Pubitemid 47094384)
153. C.S. Hinrichs, D.C. Palmer, S.A. Rosenberg, and N.P. Restifo Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells J Immunother 28 2005 517 524 (Pubitemid 41533084)
154. M.J. Dobrzanski, J.B. Reome, J.C. Hylind, K.A. Rewers-Felkins, K. Abulsamad, and S.L. Adams Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating differentiated T cell localization, activation and chemokine production in established breast cancer Clin Immunol 128 2008 205 218
155. D. Wang, M. Wang, Y. Cheng, and G.A. Fitzgerald Cardiovascular hazard and non-steroidal anti-inflammatory drugs Curr Opin Pharmacol 5 2005 204 210 (Pubitemid 40378754)
156. R. Mosenden, and K. Tasken Cyclic AMP-mediated immune regulation - overview of mechanisms of action in T cells Cell Signal 23 2010 1009 1016
157. R.L. Jones, M.A. Giembycz, and D.F. Woodward Prostanoid receptor antagonists: development strategies and therapeutic applications Br J Pharmacol 158 2009 104 145
158. K. Af Forselles, J. Root, T. Clarke, D. Davey, K. Aughton, and K. Dack In vitro and in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP(2) receptor antagonist Br J Pharmacol 164 2011 1847 1856
159. H. Makita, M. Mutoh, T. Maruyama, K. Yonemoto, A. Kobayashi, and H. Fujitsuka A prostaglandin E2 receptor subtype EP1-selective antagonist, ONO-8711, suppresses 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis Carcinogenesis 28 2007 677 684 (Pubitemid 46523364)
160. N. Niho, M. Mutoh, T. Kitamura, M. Takahashi, H. Sato, and H. Yamamoto Suppression of azoxymethane-induced colon cancer development in rats by a prostaglandin E receptor EP1-selective antagonist Cancer Sci 96 2005 260 264 (Pubitemid 40895073)
161. H. Hoshikawa, R. Goto, T. Mori, T. Mitani, and N. Mori Expression of prostaglandin E2 receptors in oral squamous cell carcinomas and growth inhibitory effects of an EP3 selective antagonist, ONO-AE3-240 Int J Oncol 34 2009 847 852
162. A.M. Fulton, X. Ma, and N. Kundu Targeting prostaglandin E EP receptors to inhibit metastasis Cancer Res 66 2006 9794 9797 (Pubitemid 44672027)
163. N. Kundu, X. Ma, D. Holt, O. Goloubeva, S. Ostrand-Rosenberg, and A.M. Fulton Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function Breast Cancer Res Treat 117 2009 235 242
164. X. Ma, N. Kundu, S. Rifat, T. Walser, and A.M. Fulton Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis Cancer Res 66 2006 2923 2927